基地錦標集團(08460.HK)擬增加法定股本後按"1供3"進行供股
格隆匯2月23日丨基地錦標集團(08460.HK)公吿,董事會建議將公司法定股本由30,000,000港元(分為300,000,000股股份)增加至300,000,000港元(分為3,000,000,000股股份)。待股東於股東特別大會上通過普通決議案批准增加法定股本後,增加法定股本將於股東特別大會日期生效。股份於聯交所買賣每手買賣單位由10,000股股份更改為20,000股股份。
待增加法定股本生效後,公司建議按於記錄日期每持有一(1)股現有股份獲發三(3)股供股股份的基準進行供股,以每股供股股份0.12港元的認購價發行最多3.45億股供股股份,藉此籌集所得款項總額最多約4140萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.